Implications of Gut Microbiota in Neurodegenerative Diseases

Zhang, Haoming; Chen, Yijia; Wang, Zifan; Xie, Gaijie; Liu, Mingming; Yuan, Boyu; Chai, Hongxia; Wang, Wei; Cheng, Ping

doi:10.3389/fimmu.2022.785644

Cited by 75 publications

(52 citation statements)

References 207 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impaired intestinal wall and blood-brain barriers and gut microbiota alterations are also linked to PD pathology. An increased presence of Lactobacillaceae, Barnesiellaceae, and Enterococcaceae and a decreased presence of Clostridium coccoides, Bacteroides fragilis, and Prevotellaceae have been observed in PD patients compared with healthy controls [44,45].…”

Section: Discussionmentioning

confidence: 99%

The Risk of Developing Alzheimer’s Disease and Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis

Szandruk-Bender

Wiatrak

Szeląg

2022

JCM

View full text Add to dashboard Cite

Recently, a growing body of research has linked gut microbiota dysbiosis to central nervous system diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), and has suggested that AD and PD pathology may take its origin from chronic inflammation in the gastrointestinal tract. Thus, this study aimed to elucidate whether inflammatory bowel disease (IBD) is associated with a higher risk of developing AD and PD as compared to the non-IBD population by conducting a meta-analysis. A thorough search of Pubmed and Embase databases was performed to identify all relevant articles. The quality of included studies was assessed using the Newcastle-Ottawa Scale. The odds ratios (ORs) with 95% confidence intervals (CIs) were analyzed using a fixed-effect model. To assess publication bias and heterogeneity among the studies, Egger’s test and L’Abbé plots were used, respectively. A total of eight eligible studies were included in this meta-analysis. No significant heterogeneity or significant publication bias was detected. The risk of developing AD in IBD patients was higher than in non-IBD patients (OR = 0.37; 95% CI = 0.14–1.00; p = 0.05), and there was a relationship between the occurrence of AD and Crohn’s disease or ulcerative colitis (OR = 0.11; 95% CI = 0.04–0.30; p < 0.0001, OR = 0.14; 95% CI = 0.04–0.49; p = 0.0024, respectively). The risk of developing both of the most common neurodegenerative diseases, AD and PD, was also significantly higher in patients diagnosed with Crohn’s disease or ulcerative colitis (OR = 0.21; 95% CI = 0.09–0.49; p = 0.0003, OR = 0.25; 95% CI = 0.13–0.51; p = 0.0001, respectively). This meta-analysis revealed a higher risk of AD and PD among CD and UC patients compared to the general population. It may suggest a key role for the gut microbiota in the pathogenesis of not only Crohn’s disease and ulcerative colitis but also AD and PD. The identification of this potential risk may provide earlier preventive measures to be implemented to reduce comorbidity and mortality rate.

show abstract

Section: Discussionmentioning

confidence: 99%

The Risk of Developing Alzheimer’s Disease and Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis

Szandruk-Bender

Wiatrak

Szeląg

2022

JCM

View full text Add to dashboard Cite

show abstract

“…The imbalance in the composition of the intestinal microbiota is called intestinal dysbiosis and triggers a cascade of dysfunctional processes, including neuropsychiatric symptoms of neurodegenerative diseases such as AD ( 33 – 36 ) ( Figure 1 ).…”

Section: Gut Microbiota Aging and Alzheimer's Diseasementioning

confidence: 99%

The Gut Microbiota-Brain Axis: A New Frontier on Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder of integrative areas of the brain, characterized by cognitive decline and disability resulting in negative impacts on the family of the patients and the health care services worldwide. AD involves oxidative stress, neuroinflammation and accelerated apoptosis, accompanied by deposition of amyloid-β peptide plaques and tau protein-based neurofibrillary tangles in the central nervous system. Among the multiple factors that contribute to the onset and evolution of this disease, aging stands out. That is why the prevalence of this disease has increased due to the constant increase in life expectancy. In the hope of finding new, more effective methods to slow the progression of this disease, over the last two decades, researchers have promoted “omics”-based approaches that include the gut microbiota and their reciprocal interactions with different targets in the body. This scientific advance has also led to a better understanding of brain compartments and the mechanisms that affect the integrity of the blood-brain barrier. This review aims to discuss recent advances related to the gut-brain-microbiota axis in AD. Furthermore, considering that AD involves psychiatric symptoms, this review also focuses on the psychiatric factors that interact with this axis (an issue that has not yet been sufficiently addressed in the literature).

show abstract

“…The gut microbiome impacts brain functions, impaired BBB, altered synaptic plasticity, microglial activity, neurogenesis, neurotransmitter production, and behavioral effects ( Luczynski et al, 2016 ; Chu et al, 2019 ). According to recent research, the intestinal microbiome significantly impacts the pathogenesis of depression symptoms in rats via the BGM axis ( Zhang et al, 2022 ). Furthermore, changes in the BGM axis may also influence the progression of neurodegenerative diseases ( Kowalski and Mulak, 2019 ).…”

Section: Brain-gut-microbiome Axis and Neurotransmittersmentioning

confidence: 99%

A review of the preclinical and clinical studies on the role of the gut microbiome in aging and neurodegenerative diseases and its modulation

Hashim

Makpol

2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

As the world population ages, the burden of age-related health problems grows, creating a greater demand for new novel interventions for healthy aging. Advancing aging is related to a loss of beneficial mutualistic microbes in the gut microbiota caused by extrinsic and intrinsic factors such as diet, sedentary lifestyle, sleep deprivation, circadian rhythms, and oxidative stress, which emerge as essential elements in controlling and prolonging life expectancy of healthy aging. This condition is known as gut dysbiosis, and it affects normal brain function via the brain-gut microbiota (BGM) axis, which is a bidirectional link between the gastrointestinal tract (GIT) and the central nervous system (CNS) that leads to the emergence of brain disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Here, we reviewed the role of the gut microbiome in aging and neurodegenerative diseases, as well as provided a comprehensive review of recent findings from preclinical and clinical studies to present an up-to-date overview of recent advances in developing strategies to modulate the intestinal microbiome by probiotic administration, dietary intervention, fecal microbiota transplantation (FMT), and physical activity to address the aging process and prevent neurodegenerative diseases. The findings of this review will provide researchers in the fields of aging and the gut microbiome design innovative studies that leverage results from preclinical and clinical studies to better understand the nuances of aging, gut microbiome, and neurodegenerative diseases.

show abstract

Implications of Gut Microbiota in Neurodegenerative Diseases

Cited by 75 publications

References 207 publications

The Risk of Developing Alzheimer’s Disease and Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis

The Risk of Developing Alzheimer’s Disease and Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis

The Gut Microbiota-Brain Axis: A New Frontier on Neuropsychiatric Disorders

A review of the preclinical and clinical studies on the role of the gut microbiome in aging and neurodegenerative diseases and its modulation

Contact Info

Product

Resources

About